Pharmerging

Pharmerging Comprehensive Study by Type (Pharmaceuticals, Healthcare), Distribution Channel (Hospitals, Retail Pharmacies, Online Stores, Others), Indications (Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, Others) Players and Region - Global Market Outlook to 2030

Pharmerging Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pharmerging
Pharmerging is an IQVIA group. Pharmerging is a time period used to describe a crew of international locations with a bad role in the pharmaceutical area however fast expansion. China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, and others are some of the most necessary pharmerging markets. The demand for drug treatments in pharmerging has been inspired by using growing older populations, rising healthcare expenditures, a upward jostle in the variety of public hospitals, and an extend in the sickness burden of persistent diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.9%


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pharmerging market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), GlaxoSmithKline (United Kingdom), Pfizer (United States), Sanofi (France), Novartis (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Tata Consultancy Services Ltd. (India), LUPIN (India), Teva Pharmaceutical Industries Ltd. (Israel) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Koninklijke (Netherlands), Philips N.V. (Netherlands) and Abbott Laboratories (United States).

Segmentation Overview
AMA Research has segmented the market of Global Pharmerging market by Type (Pharmaceuticals and Healthcare) and Region.



On the basis of geography, the market of Pharmerging has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospitals will boost the Pharmerging market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indications, the sub-segment i.e. Lifestyle Diseases will boost the Pharmerging market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Geriatric Population

Market Growth Drivers:
Increasing Healthcare Expenditures and Rising Number of Private Hospitals

Challenges:
Need for Qualified Workforce and Reduced Demand for Prescription Medicine

Restraints:
Higher Cost of the Research and Development and Complex Government Approval Process

Opportunities:
Introduction of Advanced Treatments

Market Leaders and their expansionary development strategies
In June 2022, Abbott Laboratories announced that they are developing a new type of biowearable that will continuously monitor glucose level and ketone levels in one sensor. The device has secured with the breakthrough from the U.S. Food and Drug Administration, which is designed to expedite the review of innovative technologies that will improve the life of people.
In 2021, Johnson & Johnson announced its intent to separate the Company’s Consumer Health business, creating a new publicly traded company. The planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.


Key Target Audience
Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pharmaceuticals
  • Healthcare
By Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Online Stores
  • Others

By Indications
  • Lifestyle Diseases
  • Cancer and Autoimmune Diseases
  • Infectious Diseases
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Healthcare Expenditures
      • 3.2.2. Rising Number of Private Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Need for Qualified Workforce
      • 3.3.2. Reduced Demand for Prescription Medicine
    • 3.4. Market Trends
      • 3.4.1. Growing Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmerging, by Type, Distribution Channel, Indications and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pharmerging (Value)
      • 5.2.1. Global Pharmerging by: Type (Value)
        • 5.2.1.1. Pharmaceuticals
        • 5.2.1.2. Healthcare
      • 5.2.2. Global Pharmerging by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Stores
        • 5.2.2.4. Others
      • 5.2.3. Global Pharmerging by: Indications (Value)
        • 5.2.3.1. Lifestyle Diseases
        • 5.2.3.2. Cancer and Autoimmune Diseases
        • 5.2.3.3. Infectious Diseases
        • 5.2.3.4. Others
      • 5.2.4. Global Pharmerging Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pharmerging: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Tata Consultancy Services Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LUPIN (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pharmerging Sale, by Type, Distribution Channel, Indications and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Pharmerging (Value)
      • 7.2.1. Global Pharmerging by: Type (Value)
        • 7.2.1.1. Pharmaceuticals
        • 7.2.1.2. Healthcare
      • 7.2.2. Global Pharmerging by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Stores
        • 7.2.2.4. Others
      • 7.2.3. Global Pharmerging by: Indications (Value)
        • 7.2.3.1. Lifestyle Diseases
        • 7.2.3.2. Cancer and Autoimmune Diseases
        • 7.2.3.3. Infectious Diseases
        • 7.2.3.4. Others
      • 7.2.4. Global Pharmerging Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharmerging: by Type(USD Million)
  • Table 2. Pharmerging Pharmaceuticals , by Region USD Million (2018-2023)
  • Table 3. Pharmerging Healthcare , by Region USD Million (2018-2023)
  • Table 4. Pharmerging: by Distribution Channel(USD Million)
  • Table 5. Pharmerging Hospitals , by Region USD Million (2018-2023)
  • Table 6. Pharmerging Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 7. Pharmerging Online Stores , by Region USD Million (2018-2023)
  • Table 8. Pharmerging Others , by Region USD Million (2018-2023)
  • Table 9. Pharmerging: by Indications(USD Million)
  • Table 10. Pharmerging Lifestyle Diseases , by Region USD Million (2018-2023)
  • Table 11. Pharmerging Cancer and Autoimmune Diseases , by Region USD Million (2018-2023)
  • Table 12. Pharmerging Infectious Diseases , by Region USD Million (2018-2023)
  • Table 13. Pharmerging Others , by Region USD Million (2018-2023)
  • Table 14. South America Pharmerging, by Country USD Million (2018-2023)
  • Table 15. South America Pharmerging, by Type USD Million (2018-2023)
  • Table 16. South America Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 17. South America Pharmerging, by Indications USD Million (2018-2023)
  • Table 18. Brazil Pharmerging, by Type USD Million (2018-2023)
  • Table 19. Brazil Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 20. Brazil Pharmerging, by Indications USD Million (2018-2023)
  • Table 21. Argentina Pharmerging, by Type USD Million (2018-2023)
  • Table 22. Argentina Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 23. Argentina Pharmerging, by Indications USD Million (2018-2023)
  • Table 24. Rest of South America Pharmerging, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 26. Rest of South America Pharmerging, by Indications USD Million (2018-2023)
  • Table 27. Asia Pacific Pharmerging, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Pharmerging, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 30. Asia Pacific Pharmerging, by Indications USD Million (2018-2023)
  • Table 31. China Pharmerging, by Type USD Million (2018-2023)
  • Table 32. China Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 33. China Pharmerging, by Indications USD Million (2018-2023)
  • Table 34. Japan Pharmerging, by Type USD Million (2018-2023)
  • Table 35. Japan Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 36. Japan Pharmerging, by Indications USD Million (2018-2023)
  • Table 37. India Pharmerging, by Type USD Million (2018-2023)
  • Table 38. India Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 39. India Pharmerging, by Indications USD Million (2018-2023)
  • Table 40. South Korea Pharmerging, by Type USD Million (2018-2023)
  • Table 41. South Korea Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 42. South Korea Pharmerging, by Indications USD Million (2018-2023)
  • Table 43. Taiwan Pharmerging, by Type USD Million (2018-2023)
  • Table 44. Taiwan Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 45. Taiwan Pharmerging, by Indications USD Million (2018-2023)
  • Table 46. Australia Pharmerging, by Type USD Million (2018-2023)
  • Table 47. Australia Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 48. Australia Pharmerging, by Indications USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Pharmerging, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Pharmerging, by Indications USD Million (2018-2023)
  • Table 52. Europe Pharmerging, by Country USD Million (2018-2023)
  • Table 53. Europe Pharmerging, by Type USD Million (2018-2023)
  • Table 54. Europe Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 55. Europe Pharmerging, by Indications USD Million (2018-2023)
  • Table 56. Germany Pharmerging, by Type USD Million (2018-2023)
  • Table 57. Germany Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 58. Germany Pharmerging, by Indications USD Million (2018-2023)
  • Table 59. France Pharmerging, by Type USD Million (2018-2023)
  • Table 60. France Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 61. France Pharmerging, by Indications USD Million (2018-2023)
  • Table 62. Italy Pharmerging, by Type USD Million (2018-2023)
  • Table 63. Italy Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 64. Italy Pharmerging, by Indications USD Million (2018-2023)
  • Table 65. United Kingdom Pharmerging, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 67. United Kingdom Pharmerging, by Indications USD Million (2018-2023)
  • Table 68. Netherlands Pharmerging, by Type USD Million (2018-2023)
  • Table 69. Netherlands Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 70. Netherlands Pharmerging, by Indications USD Million (2018-2023)
  • Table 71. Rest of Europe Pharmerging, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 73. Rest of Europe Pharmerging, by Indications USD Million (2018-2023)
  • Table 74. MEA Pharmerging, by Country USD Million (2018-2023)
  • Table 75. MEA Pharmerging, by Type USD Million (2018-2023)
  • Table 76. MEA Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 77. MEA Pharmerging, by Indications USD Million (2018-2023)
  • Table 78. Middle East Pharmerging, by Type USD Million (2018-2023)
  • Table 79. Middle East Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 80. Middle East Pharmerging, by Indications USD Million (2018-2023)
  • Table 81. Africa Pharmerging, by Type USD Million (2018-2023)
  • Table 82. Africa Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 83. Africa Pharmerging, by Indications USD Million (2018-2023)
  • Table 84. North America Pharmerging, by Country USD Million (2018-2023)
  • Table 85. North America Pharmerging, by Type USD Million (2018-2023)
  • Table 86. North America Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 87. North America Pharmerging, by Indications USD Million (2018-2023)
  • Table 88. United States Pharmerging, by Type USD Million (2018-2023)
  • Table 89. United States Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 90. United States Pharmerging, by Indications USD Million (2018-2023)
  • Table 91. Canada Pharmerging, by Type USD Million (2018-2023)
  • Table 92. Canada Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 93. Canada Pharmerging, by Indications USD Million (2018-2023)
  • Table 94. Mexico Pharmerging, by Type USD Million (2018-2023)
  • Table 95. Mexico Pharmerging, by Distribution Channel USD Million (2018-2023)
  • Table 96. Mexico Pharmerging, by Indications USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Pharmerging: by Type(USD Million)
  • Table 108. Pharmerging Pharmaceuticals , by Region USD Million (2025-2030)
  • Table 109. Pharmerging Healthcare , by Region USD Million (2025-2030)
  • Table 110. Pharmerging: by Distribution Channel(USD Million)
  • Table 111. Pharmerging Hospitals , by Region USD Million (2025-2030)
  • Table 112. Pharmerging Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 113. Pharmerging Online Stores , by Region USD Million (2025-2030)
  • Table 114. Pharmerging Others , by Region USD Million (2025-2030)
  • Table 115. Pharmerging: by Indications(USD Million)
  • Table 116. Pharmerging Lifestyle Diseases , by Region USD Million (2025-2030)
  • Table 117. Pharmerging Cancer and Autoimmune Diseases , by Region USD Million (2025-2030)
  • Table 118. Pharmerging Infectious Diseases , by Region USD Million (2025-2030)
  • Table 119. Pharmerging Others , by Region USD Million (2025-2030)
  • Table 120. South America Pharmerging, by Country USD Million (2025-2030)
  • Table 121. South America Pharmerging, by Type USD Million (2025-2030)
  • Table 122. South America Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 123. South America Pharmerging, by Indications USD Million (2025-2030)
  • Table 124. Brazil Pharmerging, by Type USD Million (2025-2030)
  • Table 125. Brazil Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 126. Brazil Pharmerging, by Indications USD Million (2025-2030)
  • Table 127. Argentina Pharmerging, by Type USD Million (2025-2030)
  • Table 128. Argentina Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 129. Argentina Pharmerging, by Indications USD Million (2025-2030)
  • Table 130. Rest of South America Pharmerging, by Type USD Million (2025-2030)
  • Table 131. Rest of South America Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 132. Rest of South America Pharmerging, by Indications USD Million (2025-2030)
  • Table 133. Asia Pacific Pharmerging, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Pharmerging, by Type USD Million (2025-2030)
  • Table 135. Asia Pacific Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 136. Asia Pacific Pharmerging, by Indications USD Million (2025-2030)
  • Table 137. China Pharmerging, by Type USD Million (2025-2030)
  • Table 138. China Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 139. China Pharmerging, by Indications USD Million (2025-2030)
  • Table 140. Japan Pharmerging, by Type USD Million (2025-2030)
  • Table 141. Japan Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 142. Japan Pharmerging, by Indications USD Million (2025-2030)
  • Table 143. India Pharmerging, by Type USD Million (2025-2030)
  • Table 144. India Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 145. India Pharmerging, by Indications USD Million (2025-2030)
  • Table 146. South Korea Pharmerging, by Type USD Million (2025-2030)
  • Table 147. South Korea Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 148. South Korea Pharmerging, by Indications USD Million (2025-2030)
  • Table 149. Taiwan Pharmerging, by Type USD Million (2025-2030)
  • Table 150. Taiwan Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 151. Taiwan Pharmerging, by Indications USD Million (2025-2030)
  • Table 152. Australia Pharmerging, by Type USD Million (2025-2030)
  • Table 153. Australia Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 154. Australia Pharmerging, by Indications USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Pharmerging, by Type USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Pharmerging, by Indications USD Million (2025-2030)
  • Table 158. Europe Pharmerging, by Country USD Million (2025-2030)
  • Table 159. Europe Pharmerging, by Type USD Million (2025-2030)
  • Table 160. Europe Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 161. Europe Pharmerging, by Indications USD Million (2025-2030)
  • Table 162. Germany Pharmerging, by Type USD Million (2025-2030)
  • Table 163. Germany Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 164. Germany Pharmerging, by Indications USD Million (2025-2030)
  • Table 165. France Pharmerging, by Type USD Million (2025-2030)
  • Table 166. France Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 167. France Pharmerging, by Indications USD Million (2025-2030)
  • Table 168. Italy Pharmerging, by Type USD Million (2025-2030)
  • Table 169. Italy Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 170. Italy Pharmerging, by Indications USD Million (2025-2030)
  • Table 171. United Kingdom Pharmerging, by Type USD Million (2025-2030)
  • Table 172. United Kingdom Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 173. United Kingdom Pharmerging, by Indications USD Million (2025-2030)
  • Table 174. Netherlands Pharmerging, by Type USD Million (2025-2030)
  • Table 175. Netherlands Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 176. Netherlands Pharmerging, by Indications USD Million (2025-2030)
  • Table 177. Rest of Europe Pharmerging, by Type USD Million (2025-2030)
  • Table 178. Rest of Europe Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 179. Rest of Europe Pharmerging, by Indications USD Million (2025-2030)
  • Table 180. MEA Pharmerging, by Country USD Million (2025-2030)
  • Table 181. MEA Pharmerging, by Type USD Million (2025-2030)
  • Table 182. MEA Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 183. MEA Pharmerging, by Indications USD Million (2025-2030)
  • Table 184. Middle East Pharmerging, by Type USD Million (2025-2030)
  • Table 185. Middle East Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 186. Middle East Pharmerging, by Indications USD Million (2025-2030)
  • Table 187. Africa Pharmerging, by Type USD Million (2025-2030)
  • Table 188. Africa Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 189. Africa Pharmerging, by Indications USD Million (2025-2030)
  • Table 190. North America Pharmerging, by Country USD Million (2025-2030)
  • Table 191. North America Pharmerging, by Type USD Million (2025-2030)
  • Table 192. North America Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 193. North America Pharmerging, by Indications USD Million (2025-2030)
  • Table 194. United States Pharmerging, by Type USD Million (2025-2030)
  • Table 195. United States Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 196. United States Pharmerging, by Indications USD Million (2025-2030)
  • Table 197. Canada Pharmerging, by Type USD Million (2025-2030)
  • Table 198. Canada Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 199. Canada Pharmerging, by Indications USD Million (2025-2030)
  • Table 200. Mexico Pharmerging, by Type USD Million (2025-2030)
  • Table 201. Mexico Pharmerging, by Distribution Channel USD Million (2025-2030)
  • Table 202. Mexico Pharmerging, by Indications USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharmerging: by Type USD Million (2018-2023)
  • Figure 5. Global Pharmerging: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Pharmerging: by Indications USD Million (2018-2023)
  • Figure 7. South America Pharmerging Share (%), by Country
  • Figure 8. Asia Pacific Pharmerging Share (%), by Country
  • Figure 9. Europe Pharmerging Share (%), by Country
  • Figure 10. MEA Pharmerging Share (%), by Country
  • Figure 11. North America Pharmerging Share (%), by Country
  • Figure 12. Global Pharmerging share by Players 2023 (%)
  • Figure 13. Global Pharmerging share by Players (Top 3) 2023(%)
  • Figure 14. Global Pharmerging share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2023
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2023
  • Figure 24. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 26. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 27. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 28. Tata Consultancy Services Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 29. Tata Consultancy Services Ltd. (India) Revenue: by Geography 2023
  • Figure 30. LUPIN (India) Revenue, Net Income and Gross profit
  • Figure 31. LUPIN (India) Revenue: by Geography 2023
  • Figure 32. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 33. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 34. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 36. Global Pharmerging: by Type USD Million (2025-2030)
  • Figure 37. Global Pharmerging: by Distribution Channel USD Million (2025-2030)
  • Figure 38. Global Pharmerging: by Indications USD Million (2025-2030)
  • Figure 39. South America Pharmerging Share (%), by Country
  • Figure 40. Asia Pacific Pharmerging Share (%), by Country
  • Figure 41. Europe Pharmerging Share (%), by Country
  • Figure 42. MEA Pharmerging Share (%), by Country
  • Figure 43. North America Pharmerging Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • GlaxoSmithKline (United Kingdom)
  • Pfizer (United States)
  • Sanofi (France)
  • Novartis (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Tata Consultancy Services Ltd. (India)
  • LUPIN (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Koninklijke (Netherlands) , Philips N.V. (Netherlands) , Abbott Laboratories (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 241 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Pharmerging Quantitative research analysis
Pharmerging Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), GlaxoSmithKline (United Kingdom), Pfizer (United States), Sanofi (France), Novartis (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Tata Consultancy Services Ltd. (India), LUPIN (India), Teva Pharmaceutical Industries Ltd. (Israel) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Geriatric Population" is seen as one of major influencing trends for Pharmerging Market during projected period 2023-2030.
The Pharmerging market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Pharmerging Report?

Have a Query? Click Here

Other Related Reports

3D Medical Printing Systems Comprehensive Study by Type (Surgical Guides, Dental Guides, Craniomaxillofacial Guides, Orthopedic Guides, Surgical Instruments, Retractors, Others), Application (Hospita...
$ 3750
Diagnostic Imaging Services Comprehensive Study by Type (X-Ray, Magnetic Resonance Imaging (MRI), Ultrasound, Radionuclide), Application (General Radiography, Dentistry, Fluoroscopy, Neurology, Ortho...
$ 3650
In-Vitro Diagnostics Products Comprehensive Study by Type (Hematology Analyzer and Reagents, Chemistry Analyzer and Reagents, Hemoglobin System), Application (Autoimmune diseases, Cardiology, Diabete...
$ 3750
Food Allergen Testing Kits Comprehensive Study by Type (Polymerase Chain Reaction (PCR)-based, Immunoassay-based/ELISA, Others), Application (Bakery & Confectionery, Infant Food, Processed Food, Dair...
$ 3750
Zirconia Implant Comprehensive Study by Type (Single-stage Zirconia Implants, Two-stage Zirconia Implants), Application (Hospital, Dental Clinic), Form (Plate-Form, Root-Form) Players and Region - Gl...
$ 3500
Specimen Validity Testing Comprehensive Study by Type (Laboratory Testing, Rapid/POC Testing), Application (Workplaces, Drug Screening Laboratories, Criminal Justice and Law Enforcement Agencies, Pai...
$ 3650